PRT12396

Phase 1Small molecule

PPrelude Therapeutics

PRT12396 is one of 4 small molecule programs targeting Polycythemia Vera (PV). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia Vera (PV)Recruiting

Polycythemia Vera (PV)Phase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Polycythemia Vera (PV)

#DrugCompanyPhaseTrials

Jakafi

Incyte

Phase 2

1 2

Flonoltinib

CChengdu Zenitar Biomedical Technology Co., Ltd

Phase 2

1 3

DISC-3405

DDisc Medicine, Inc

Phase 2

1 4

PRT12396

PPrelude Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Polycythemia Vera (PV)

NCT07469891

Clinical

Trials by Indication[1]

Polycythemia Vera (PV)1 trial

A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis

Recruiting·PPrelude Therapeutics·Phase 1·NCT07469891·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PRT12396. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRT12396 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRT12396. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prelude Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPrelude Therapeutics

PRT12396

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Polycythemia Vera (PV)1 trial

References

Drug Info

Quick Facts

Related News